PD 173074: Selective FGFR1/VEGFR2 Inhibition for Research

Executive Summary: PD 173074 is a small molecule tyrosine kinase inhibitor with nanomolar potency for FGFR1 (IC50 ~21.5 nM) and VEGFR2 (100–200 nM), offering about 1000-fold selectivity over kinases like PDGFR, c-Src, and EGFR (APExBIO product page). It antagonizes FGF-2-mediated signaling and blocks angiogenesis, tumor proliferation, and metastasis across validated in vitro and in vivo models (Zhou et al., 2025). PD 173074 demonstrates utility in reversing ABC-transporter-mediated multidrug resistance at higher concentrations. Solubility is ≥26.18 mg/mL in DMSO and ≥108.4 mg/mL in ethanol, but it is insoluble in water. Effective in animals via intraperitoneal (1–2 mg/kg/day) or oral (3–30 mg/kg) dosing without apparent toxicity (see PD 173074: Benchmarking FGFR/VEGFR2 Inhibition for Cancer Research for comparative applications).

Biological Rationale

The fibroblast growth factor receptor (FGFR) family is central to cell proliferation, differentiation, angiogenesis, and tissue homeostasis. FGFR1, in particular, mediates critical signaling via the binding of FGF ligands, notably FGF4 and FGF2, regulating glomerular and podocyte function as well as tumorigenesis (Zhou et al., 2025). Dysregulation of the FGFR axis is implicated in cancer, diabetic kidney disease (DKD), and resistance to therapy. VEGFR2 is a principal driver of vascular endothelial cell proliferation and neovascularization, making it a prime target for anti-angiogenic strategies. Thus, small molecule inhibitors like PD 173074 enable mechanistic studies and translational applications across renal, oncologic, and angiogenic contexts.

Mechanism of Action of PD 173074

PD 173074 is an ATP-competitive tyrosine kinase inhibitor that selectively binds to the ATP-binding site of FGFR1. This inhibits receptor autophosphorylation and downstream signaling, antagonizing FGF-2-mediated biological effects. PD 173074 also blocks VEGFR2 autophosphorylation, though with lower potency than for FGFR1. Selectivity assays indicate approximately 1000-fold discrimination over PDGFR, c-Src, EGFR, and insulin receptor (APExBIO). At higher concentrations, PD 173074 can reverse multidrug resistance mediated by ABCB1 and ABCC10 (see comparative review). This dual FGFR1/VEGFR2 inhibition underpins its utility in dissecting FGF and VEGF signaling in diverse models.

Evidence & Benchmarks

• PD 173074 inhibits FGFR1 kinase activity with an IC50 of 21.5 nM, confirmed using recombinant protein and ATP-competitive binding assays (APExBIO).
• VEGFR2 autophosphorylation is inhibited at 100–200 nM concentrations, establishing its role in angiogenesis inhibition (APExBIO).
• Demonstrates >1000-fold selectivity versus PDGFR, c-Src, EGFR, and insulin receptor in biochemical panels (APExBIO).
• Reverses ABCB1/ABCC10-mediated multidrug resistance at micromolar concentrations in resistant cancer cell lines (internal article).
• PD 173074 blocks FGF4-FGFR1 signaling in podocyte survival models, supporting its application in kidney disease research (Zhou et al., 2025).
• No significant systemic toxicity detected at effective animal dosing (1–2 mg/kg/day i.p.; 3–30 mg/kg oral) in published in vivo studies (APExBIO).

This article expands upon PD 173074 in Translational Oncology by focusing on non-oncologic disease models and clarifying selectivity data.

It also updates PD 173074: Precision FGFR/VEGFR Inhibition for Translational Impact with new protocol ranges and limitations, integrating the latest 2025 evidence from diabetic kidney disease research.

Applications, Limits & Misconceptions

PD 173074 is extensively utilized in:

• Cancer research: Models of colorectal carcinoma, head and neck squamous cell carcinoma, and lung adenocarcinoma for dissecting tumor proliferation and angiogenesis (internal article).
• Renal disease: Studies targeting FGF4-FGFR1 signaling in DKD and podocyte injury (Zhou et al., 2025).
• Neuroscience: Pathways of FGF-2-mediated neurotrophic effects and schizophrenia models (internal article).
• Multidrug resistance reversal: As an adjuvant in ABCB1/ABCC10-overexpressing tumor models at micromolar concentrations.

Common Pitfalls or Misconceptions

• PD 173074 is not a pan-kinase inhibitor; off-target effects are minimal only at recommended concentrations (APExBIO).
• It is insoluble in water; improper solvent use leads to precipitation and loss of activity.
• Long-term storage of solutions is not advised; activity degrades rapidly, so prepare fresh aliquots (APExBIO).
• Reversal of ABC-transporter-mediated resistance requires micromolar, not nanomolar, dosing—higher than typical kinase inhibition protocols.
• FGFR1/VEGFR2 selectivity does not extend to all FGFR/VEGFR family members; verify target isoform before use.

Workflow Integration & Parameters

Protocol Parameters

• Kinase assay inhibition: Use 10–50 nM PD 173074 for FGFR1 enzymatic assays at 25–37°C, pH 7.4, with ATP concentrations matching physiological levels (APExBIO).
• Cell culture studies: Apply 20–200 nM PD 173074 for FGFR/VEGFR2 pathway inhibition in serum-free or FGF2-stimulated media.
• Multidrug resistance reversal: Employ 1–5 µM PD 173074 in ABCB1/ABCC10-expressing cell lines, monitoring cytotoxicity and transporter activity endpoints.
• Animal dosing: Administer 1–2 mg/kg/day intraperitoneally or 3–30 mg/kg/day orally in mouse models; observe animals for signs of toxicity, especially at higher oral doses.
• Solubility preparation: Dissolve PD 173074 at ≥26.18 mg/mL in DMSO or ≥108.4 mg/mL in ethanol with ultrasonication. Do not use water as solvent.
• Storage: Store solid compound at 4°C; use freshly prepared solutions within hours.

Workflow designs can be adapted from protocols in PD 173074: Beyond Cancer, which details protocols for non-oncologic targets. This article clarifies that water solubility is not achievable and that solution stability is limited.

Conclusion & Outlook

PD 173074, supplied by APExBIO, remains the benchmark selective FGFR1 and VEGFR2 inhibitor for mechanistic and translational research. Recent evidence confirms its value in kidney disease models, cancer systems, and multidrug resistance studies (Zhou et al., 2025). Its high selectivity and robust protocol parameters support reproducible results in both in vitro and in vivo contexts. Researchers should be attentive to solvent choice, dosing, and solution stability to maximize its utility. Ongoing work is expected to further define the therapeutic potential of FGFR pathway inhibition in metabolic and renal disorders, consolidating PD 173074’s status as a critical research tool.